OR WAIT null SECS
ACORN a CRO focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth.
MEMPHIS, Tenn., Nov. 10 /PRNewswire/ -- ACORN CRO, a Contract Research Organization exclusively focused on oncology, announced today that its third quarter had once again exceeded projections as the company continues to experience banner growth. "The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated. Our strong, active relationship with community oncology and its physicians along with our proprietary technology provide sponsors with a combination for success," remarked Steve Coplon, ACORN CEO.
ACORN CRO currently provides services for both specific cancer types and supportive care studies with additional projects ready to launch in the near future. Positioned for continued growth in 2009, ACORN CRO has expanded its staff and capabilities. ACORN CRO's experienced team provides sponsors with Project and Site Management; Data Management via Guardian EDC(TM); Statistics and Statistical Programming; and Medical and Scientific Writing.
Founded in community oncology and grounded with the most stringent scientific disciplines, ACORN CRO seamlessly incorporates the best of both worlds. "Though ACORN operates with a strong business model focused on operational success, scientific excellence guides our organization," according to Dr. Lee Schwartzberg, President and Chief Medical Director. Nationally recognized for his commitment to research at the community level, Dr. Schwartzberg co-founded Accelerated Community Oncology Research Network (ACORN), enabling oncologists nationwide to provide their patients the most promising research initiatives.
ACORN CRO evolved in response to sponsor requests for value-driven quality solutions and accelerated patient accruals. With a team approach, ACORN CRO lends itself to highly efficient and accurate trial operations. Close working relationships with community oncology practices enable prompt accruals.
"The trajectory of ACORN CRO for 2009 portends the most successful year for our company," stated Coplon. "We look forward to seeing sponsors at various meetings to showcase our abilities."
For additional information visit www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.
ACORN CRO is a full-service, oncology-focused contract research organization, providing value-driven, quality solutions to the pharmaceutical and biotech industry and offering unparalleled customer service in monitoring; clinical data management; statistical analysis; medical writing and project management. ACORN CRO delivers insights from key oncology opinion leaders and accelerates the research process through advanced levels of efficiency.